The global liquid biopsy market is expected to reach USD 5.4 billion in 2023 anticipated to grow at a CAGR of 15.2% during the forecast period 2023-2035.

Cancer remains a significant global health challenge, ranking as the second leading cause of death worldwide. By 2040, the World Health Organization (WHO) projects a staggering 16.3 million cancer-related deaths. Among all cancer types, breast cancer holds the highest occurrence globally, followed by lung, colorectal, and prostate cancers. Statistics from the Surveillance, Epidemiology, and End Results (SEER) program predict an 18% lifetime diagnosis rate for women with breast cancer, expecting around 297,790 new cases in 2023. To address this growing burden, various cancer research institutions actively pursue innovative methods and patient-focused approaches for early detection and treatment. Detecting cancer early is crucial for improving treatment effectiveness and increasing survival rates. While tissue biopsy has been the gold standard for diagnosis, its invasive nature?leading to discomfort, pain, and potential complications?has limited its widespread use. However, recent advancements in liquid biopsy have positioned it as a promising diagnostic technique for cancer. Over the past decade, liquid biopsy platforms have made significant progress, gaining regulatory approvals for minimally invasive blood-based tests. These tests enable early cancer detection and patient monitoring, offering accessibility and minimal invasiveness. By analyzing blood samples or other bodily fluids like urine or plasma, these tests identify genetic mutations and various circulating biomarkers, such as circulating tumor DNA, cell-free DNA, and extracellular vesicles. These non-invasive assessments are transforming cancer care, particularly for individuals in advanced cancer stages.

Report Coverage
? The report extensively examines the liquid biopsy market across various parameters including application, target disease indication, type of circulating biomarker, type of sample, end users, stage of development, type of product, type of technique, application area and key geographical regions
? It analyzes the market growth drivers, restraints, opportunities, and challenges, evaluating their impact on the industry.
? The report assesses both advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.
? Forecasting revenue for market segments in relation to four major regions is a key component of this report
? It offers a detailed outline of the research methodology used to study liquid biopsy and non-invasive cancer diagnostics, highlighting methodologies, assumptions, and quality control measures ensuring reliability and accuracy.
? Historical trends, currency fluctuations, foreign exchange impacts, economic recessions, and inflation measurements that influence the liquid biopsy market are thoroughly examined.
? Summarizing key insights from the research, the report provides a high-level view of the current status of the liquid biopsy market and its anticipated evolution in short, mid, and long terms.
? An overview of cancer statistics underscores the global disease burden, the importance of early cancer detection and screening, and explores different types of circulating biomarkers based on functionality. It also delves into emerging trends in intellectual property related to non-invasive cancer diagnostics, liquid biopsy costs, benefits, challenges, and their significance.
? The report emphasizes the necessity and significance of non-invasive cancer diagnostics, encompassing various imaging techniques, screening assays, and advanced diagnostic approaches along with their respective advantages and disadvantages.
? A detailed assessment of the liquid biopsy product market is provided based on multiple parameters such as development stage, product types (assay kits, devices, software/algorithms), sample types, techniques used, circulating biomarkers, target disease indications, applications, and key market players.
? Detailed profiles of leading liquid biopsy companies are presented, focusing on their establishment, workforce, headquarters, financial performance, product portfolio, recent developments, and future outlook.
? The report examines recent collaborations within the liquid biopsy market, considering parameters like partnership types, circulating biomarkers, target disease indications, most active players, and regional distributions.
? An in-depth analysis of funding and investments in liquid biopsy companies between 2016 and 2023 is provided, considering various parameters like funding types, target disease indications, application areas, geographic distribution, leading investors, and notable funding instances.
? A comprehensive evaluation of liquid biopsy product competitiveness is conducted based on supplier strength, product attributes, company size, and technological advancements.
? Initiatives by major pharmaceutical companies are thoroughly reviewed, focusing on areas of interest, stages of development, product types, target indications, and application areas.
? Historical acquisition activities since 2016 are examined, identifying potential acquisition targets within the industry.
? The report offers detailed insight into various non-invasive diagnostic tests, beyond liquid biopsies, offered by different companies for cancer screening and early detection.
? An in-depth examination of growth factors, potential limitations, emerging opportunities, and existing challenges influencing the liquid biopsy market is conducted.

Key Market Companies
? Amoy Diagnostics
? ArcherDX
? Biocartis
? Cell Search
? CellMax Life
? Datar Cancer Genetics
? DiaCarta, EONE-DIAGNOMICS
? Exosome Diagnostics
? GeneCast Biotechnology
? Integrated DNA Technologies
? Lucence
? MDNA Life Sciences
? Miltenyi Biotec
? NeoGenomics
? ONCODE Scientific
? OncoDNA
? QIAGEN
? PANAGENE
? Personal Genome Diagnostics
? Predicin
? ScreenCell
? Tecan
? Thermo Fisher Scientific